Peerview Clinical Pharmacology Cme/cne/cpe Audio Podcast

Go online to PeerView.com/RBD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated video activity, Dr. Stanley C. Jordan discusses the rationale for targeting IL-6 in chronic active antibody-mediated rejection, as well as the use of anti–IL-6 agents for the treatment of chronic active antibody-mediated rejection in the kidney transplant setting. Upon completion of this activity, participants should be better able to: Utilize the Banff classification to characterize the nature and extent of kidney transplant rejection in order to guide treatment; Discuss the rationale for targeting IL-6 as a therapeutic approach to chronic active antibody-mediated rejection in kidney transplant recipients; and Evaluate the efficacy, safety, and clinical potential of anti–IL-6 agents currently in development for the treatment of chronic active antibody-mediated rejection in the kidney transplant setting

Go online to PeerView.com/EZC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. An international panel of experts discusses the data on clinical outcomes, safety, and efficacy of new and emerging therapies for the treatment of myasthenia gravis. The interdisciplinary discussion focuses on FcRn modulation and personalized treatment approaches, and includes an interview with a patient who discusses her life and treatment journey with myasthenia gravis. Upon completion of this activity, participants should be better able to: Integrate new and emerging gMG-targeted therapies into treatment plans as appropriate, based on an understanding of the data on clinical outcomes, safety, and effects on quality of life; Develop a management strategy that incorporates the patient’s perspective in identifying treatment goals and choices; and Implement a safe, individualized administration protocol for the management of gMG that responds to clinical and patient-reported outc

Go online to PeerView.com/TFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this video, an expert reviews new data on the potential role of BTK inhibitors in the treatment of patients with multiple sclerosis presented at the American Academy of Neurology 2023 annual meeting. Learn how BTK inhibitors compare with anti-CD20 monoclonal antibodies and why this emerging class of DMTs may present a safe, effective, and highly selective treatment option with a low risk of opportunistic infections and possibly the ability to cross the blood–brain barrier, with results that may include a meaningful effect on proinflammatory cells in the CNS and the potential to prevent disability progression. Upon completion of this activity, participants should be better able to: Discuss the mechanism of action of Bruton tyrosine kinase (BTK) inhibitors in the targeted treatment of MS; Assess the current evidence regarding the efficacy, safety, and tolerability of BTK inhibi

Go online to PeerView.com/UNZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this discussion-based activity, two experts on ovarian cancer discuss the role of PARP inhibitors in treating advanced ovarian cancer. Upon completion of this activity, participants should be better able to: Adapt workflows to ensure that patients with ovarian cancer are receiving timely and appropriate genetic testing for BRCA, HRD, and other mutations that can help determine the role of PARP inhibitor therapy; Cite current efficacy and safety evidence on PARP inhibitors in different populations of patients with ovarian cancer; Utilize PARP inhibitors in the appropriate management of patients with ovarian cancer, including within the context of clinical trials, in accordance with current clinical evidence, guideline recommendations, mutation status, and patient needs and preferences; and Employ collaborative strategies to recognize and manage adverse events related to PARP i

Go online to PeerView.com/AZG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you updated on the leading advances in CLL care and the role nurses play in ensuring the best outcomes for patients? Find out in this PeerView Nurse MasterClass, where a panel of leading CLL hematology-oncology nurse experts present state-of-the-art evidence supporting the use of highly efficacious targeted strategies in CLL, including covalent and non-covalent BTKi as well as BCL2i. Our experts will also present a rich collection of case examples from nursing practice designed to explore how nurses can be the cornerstone of the management team. This event recorded at the annual ONS Congress was developed in collaboration with the CLL Society and will also feature a patient video testimonial on the nurse–patient relationship and the key role of nurses as patient educators during the therapeutic journey. Get updated on the advances in CLL care and earn NCPD/ILNA credit today!

Go online to PeerView.com/XUM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The timely detection and diagnosis of Alzheimer’s disease (AD) can provide patients with numerous opportunities—earlier treatment initiation, increased eligibility for clinical trials, participation in long-term care planning, and the chance to make lifestyle changes to slow cognitive decline. In this activity, based on a recent live symposium, experts discuss practical strategies for integrating cognitive screening into routine care visits and conducting more detailed cognitive evaluations that results in a written care plan with patients who fail a brief cognitive screening assessment. Experts also share guidance on working with Medicare reimbursement mechanisms to facilitate consistent and effective use of early detection tools and practical skills to counsel patients and their caregivers before, during, and after the diagnostic process. Upon completion of this activity, part

Go online to PeerView.com/WCS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in nontuberculous mycobacterial lung disease discuss diagnosis of the disease through knowledge of risk factors, comorbid conditions, and disease signs and symptoms. Through a collection of short, focused educational modules, the faculty will also discuss managing adverse events and creating personalized care plans to improve patient adherence and outcomes. Interviews with a patient will highlight the impact that NTM-LD—and proper treatment—can have on quality of life. Upon completion of this activity, participants should be better able to: Identify risk factors, comorbid conditions, and signs and symptoms of NTM-LD to facilitate early diagnosis; Work with the care team to create personalized treatment plans for patients with NTM-LD according to current guidelines and patient goals/preferences, using shared decision-making and evidence-based care; and E

Go online to PeerView.com/SJV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Can you bet on BCMA for your patients with multiple myeloma (MM)? Based on their demonstrated ability to evade resistance to prior agents and induce deep and durable responses, BCMA CAR-T constructs and bispecific antibodies have emerged as core management options for patients with MM progressing on their therapeutic journey. In collaboration with the HealthTree Foundation for Multiple Myeloma, this expert oncology nurse–led activity uses case-based teaching examples to illustrate practical strategies for the delivery of care with BCMA therapeutics while highlighting strategies for patient education and safety management. Each presentation features resources and tools from the HealthTree Foundation for Multiple Myeloma designed to overcome some of the challenges patients face, increase awareness of BCMA-directed options, and foster collaboration between professionals and patient

Go online to PeerView.com/RZN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Patients with irritable bowel syndrome with constipation (IBS-C) are often more comfortable discussing their concerns with the nurses on their healthcare team, which demonstrates the need for team-based care in order to maximize management, enhance outcomes, and improve quality of life. This activity features an expert overview of the pathophysiology of IBS-C and targets for therapy, including novel NHE3 inhibitors, as well as evidence-based treatment approaches with a focus on identifying and overcoming barriers to guideline-based care. Hear about recent advances in the diagnosis and treatment of IBS-C, specifically the mechanisms of the condition, current and emerging therapies, and coordinated approaches for overcoming barriers to care. Upon completion of this activity, participants should be better able to: Describe the pathophysiology and potential therapeutic targets for I

Go online to PeerView.com/VTJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape for bladder cancer has rapidly evolved. The largely chemotherapy-based approaches of the past are giving way to the use of immune checkpoint inhibitors, targeted agents, and antibody–drug conjugates in advanced disease, as well as bladder-sparing and perioperative approaches in early-stage disease settings. How can oncology nurses synthesize the diverse body of clinical evidence on approved and emerging strategies into the realities of real-world cancer care to successfully address the therapeutic and educational needs of patients across the disease continuum? To help nurses rise to the challenge of modern bladder cancer management, this PeerView activity, based on a recent live event and developed in collaboration with the Bladder Cancer Advocacy Network, features an interprofessional expert panel that provides overview of the rationale and clinical ev

Go online to PeerView.com/CFM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity based on a live MasterClass and Nursing Practice Forum, leading experts present concise learning modules combined with workshop-style demonstrations and case-based discussions to provide a practical framework for oncology nurses to facilitate optimal clinical integration of immunotherapies in advanced/metastatic and early-stage NSCLC, offering strategies to educate patients about this therapeutic class, mitigate acute and chronic immune-related adverse events (irAEs), and support patients through treatment and survivorship to help them achieve the best possible quality of life and outcomes. Upon completion of this activity, participants should be better able to: Describe the mechanisms of action, safety and efficacy, and current and emerging roles of immune checkpoint inhibitors (ICIs) and combinations in advanced- and early-stage NSCLC; Collaborate with the int

Go online to PeerView.com/SQN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The immune checkpoint inhibitors have started to radically transform the perioperative treatment of resectable stage I-III NSCLC, with the goals of reducing the risk of recurrence and improving cure rates in these settings. Several important phase 3 clinical trials evaluating neoadjuvant and/or adjuvant immunotherapies have already yielded impressive data, leading to regulatory approvals and new standards of care, and additional studies have recently been reported to be positive, adding to the evidence base but also increasing complexity. What do these advances mean for thoracic surgeons, medical oncologists, and other multidisciplinary specialists, and what changes in practice are needed? What challenges and unanswered questions remain? This PeerView educational activity, based on a recent live symposium, brings together top experts to evaluate the new practice-changing resear

Go online to PeerView.com/PUM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With adjuvant EGFR-targeted therapy now a new standard of care in resected stage I-III EGFR-mutated non-small cell lung cancer (NSCLC), what are the implications and considerations for the multidisciplinary, multimodal management of these patients? A panel of specialists in thoracic surgery and medical oncology consider this question as they discuss the importance of biomarker testing in early-stage lung cancer, the latest clinical evidence supporting the use of adjuvant EGFR-targeted therapy, and its potential expansion into the neoadjuvant setting, as well as other targeted therapies showing promise in perioperative settings. In addition, the panel demonstrates strategies for achieving better partnerships among thoracic surgeons, oncologists, pathologists, and other key specialists to facilitate predictive testing, clinical decision-making, and the optimal incorporation of EGF

Go online to PeerView.com/FNG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Much progress has been made in defining the genetic abnormalities and associated abnormal pathophysiology underlying the spontaneous and chronic inflammation that characterizes inflammatory bowel disease (IBD). Medications that suppress or modify immune activity form the core of effective treatment for IBD. Sphingosine-1-phosphate (S1P) receptor modulators, a small-molecule therapeutic option, provide a target-specific approach with a favorable safety profile. Multiple S1P receptor modulators are in development, and ozanimod became the first agent in this class to receive FDA approval for the treatment of moderately to severely active ulcerative colitis in 2021. In this activity, based on a recent live symposium, expert faculty will discuss the therapeutic effects of S1P receptor modulators on the underlying pathophysiology of IBD and identify patients with UC who could benefit

Go online to PeerView.com/GFT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Oncology nurse professionals play a particularly important role in providing high-quality and increasingly personalized care to patients with acute myeloid leukemia (AML)—but how current are you with the “real-world” practice of nursing care in AML? Find out in this activity, featuring an oncology nurse’s expert overview of nursing principles that can be used to modernize care and optimize the use of innovative targeted therapies (such as FLT3, IDH1/2, and BCL-2 inhibitors) across the treatment continuum. Upon completion of this activity, participants should be better able to: Recognize clinical symptoms, patient-related factors, and molecular/genetic features that influence AML treatment decisions and prognosis; Summarize efficacy and safety evidence related to novel targeted and epigenetic options for the management of newly diagnosed AML, postremission disease, and the relaps

Go online to PeerView.com/NRG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. HER2-low breast cancer, currently defined as HER2 IHC 1+ or 2+/ISH-, accounts for approximately 50% of all breast cancers. While older HER2-targeted therapies did not show efficacy in HER2-low breast cancers, novel antibody–drug conjugates (ADCs) have demonstrated remarkable activity in this setting. Because of these advances and the FDA approval of the first HER2-targeting ADC for HER2-low breast cancer, there is an urgent need to rethink the approaches to HER2 testing so that patients with HER2-low breast cancer could be identified and get a chance to benefit from the new therapeutic approach. The understanding, definitions, and testing for HER2-low status continue to evolve, and many practical challenges and unanswered questions remain. This PeerView educational activity, based on a recent live symposium, explores the most cutting-edge information on HER2-low breast cancer, p

Go online to PeerView.com/XFA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in HIV prevention and a patient advocate discuss the benefits of pre-exposure prophylaxis (PrEP) and the necessary tools for engaging patients in conversations about sexual health practices as well as strategies for improving the uptake of HIV prevention measures. Upon completion of this activity, participants should be better able to: Effectively engage clients in conversations about sexual health practices to assess HIV risk factors and support their ability to have healthy sex lives; Apply current evidence with individual client needs/preferences when integrating HIV prevention options (eg, PrEP, PEP, viral suppression, female condoms) into practice; Employ culturally competent educational and counseling strategies to improve the uptake of prevention measures among clients at increased risk for HIV infection; and Describe currently available and emer

Go online to PeerView.com/DCG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The time has come for even more precision in testing and targeted treatment of NSCLC. EGFR-mutated lung cancer is a perfect example of this need. The term "EGFR-positive lung cancer” is no longer adequate or specific enough to characterize this complex molecular subtype of lung cancer. Increased granularity is needed for both biomarker testing and targeted treatment selection for patients with different types of EGFR mutations. New agents and combinations have become available for patients with common (eg, exon 19 deletion, exon 21 L858R) and uncommon (eg, exon 20 insertions) EGFR mutations, and more are on the horizon. Novel strategies for overcoming resistance to EGFR-targeted therapies are showing great promise as well. This PeerView Live educational activity, based on a recent live symposium, explores the latest advances and future directions in biomarker-driven, individuali

Go online to PeerView.com/NHA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immunotherapy is now a highly efficacious management tool for melanoma, including in resectable stage III/IV disease, where its use is supported by phase 3 evidence and current practice guidelines. This “Clinical Consults” activity, taken from a recent surgical oncology live event, features expert-led case discussions that illustrate how to deliver effective care with established and emerging immune-based modalities in surgical settings. Linked mini lecture segments cover topics such as adjuvant immunotherapy in stage II/III melanoma; efficacy, safety, and dosing information on neoadjuvant immunotherapy; and emerging immune-based treatments in resectable melanoma (eg, PD-1/LAG-3 combinations). Watch today to learn how to identify optimal candidates for immunotherapy, address treatment selection and dosing considerations, and effectively manage immune-related events. Upon complet

Go online to PeerView.com/RGA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Although the prognosis of patients with early breast cancer (EBC) has improved with earlier detection and more efficacious therapies, many patients still face poor outcomes, and there is an urgent need to prevent recurrences. An increasing number of systemic therapies have been recently approved in the perioperative settings of HR+, HER2+, and triple-negative breast cancer (TNBC), including immunotherapy, CDK4/6 inhibitor therapy, adjuvant PARP inhibitor therapy, and a number of HER2-targeted therapies. Other agents and combinations are undergoing evaluation in clinical trials and are likely to expand the systemic therapy arsenal for patients with EBC. With the increasing complexity of systemic and local treatment of patients with EBC, it is crucial for surgeons, medical oncologists, pathologists, and other members of the breast cancer care team to effectively collaborate and co